Health Care Cost

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year.

The country has seen historic reductions in uninsured rates and improvements in affordability since the implementation of the Affordable Care Act, the Commonwealth Fund scorecard shows.

Explore how health equity and policy shape outcomes, revealing disparities in kidney disease, atopic dermatitis, and cancer care for vulnerable populations.

Risk factors for financial toxicity in a nationally representative survey included involuntary unemployment, transient loss of health insurance, and high-deductible health plans.

A private oncology shared savings plan reduced colon cancer treatment costs. Results varied by tumor, with none in breast cancer and mixed effects in lung cancer.

Patients who remained on treatment, especially at higher doses or on tirzepatide, were more likely to achieve clinically meaningful weight loss and improved glycemic control.

Adolescents face significant barriers to obesity medication access, despite a surge in prescriptions. Discover the disparities and potential solutions in obesity care.

Trump's sweeping health care overhaul faces scrutiny, risking coverage for millions while igniting bipartisan tensions over fiscal and social impacts.

The Congressional Budget Office estimates the package would add $2.4 trillion to the national deficit over a decade and leave 10.9 million more Americans without health insurance.

Tariff increases threaten the US economy and health care costs, impacting managed care affordability and member financial stability.

African American and Latino older adults with Alzheimer disease and related dementias and their families are likely to face disproportionately high burdens, primarily associated with unpaid caregiving, suggesting the need for policies that may reduce economic burdens for all US residents.

The proposed 2026 HHS budget slashes National Institutes of Health (NIH) funding by 40%, alarming health experts and threatening vital research and public health initiatives.

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price.

"Political directives should not prevent individuals from seeking safe and effective care that they desire and deserve," authors from the American College of Physicians (ACP) write.

US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to report fair or poor health, underscoring persistent disparities in worker well-being.

Racial and ethnic disparities in health access persist, highlighting the urgent need for targeted interventions to achieve health equity across various conditions.

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Community oncology faces significant challenges from the Inflation Reduction Act's (IRA) drug pricing changes, risking financial stability and patient access to care.

A new State of Drug Access report shows that more than 40% of people living in the US could not afford their prescribed drugs.

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access challenges and payer coverage trends affecting treatment options.

This week, the Center on Health Equity & Access covered news from the Trump administration and CMS, Cigna's co-pay cap on weight loss drugs, and perspectives on living with HIV.

Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug pricing initiatives.

Veterans primarily receiving care through the Department of Veterans Affairs (VA) similarly used dental and vision services under Medicare Advantage (MA) and traditional Medicare, challenging the justification for full MA capitated payments based on supplemental benefits.

Emma Achola-Kothari, PhD, highlights the need to expand Medigap access for Medicare beneficiaries younger than 65 years and calls for future research connecting access barriers to health outcomes.

The Trump administration could consider all sides of the federal rule before making a permanent decision on its potential repeal.

Emma Achola-Kothari, PhD, explains that younger Medicare beneficiaries without supplemental coverage face high costs, while dual-eligible beneficiaries in Medicare Advantage plans struggle with provider access.

The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.

Ali Khawar, former Department of Labor official, explains the original intent of a federal rule to reinforce the Mental Health Parity and Addiction Equity Act could be under threat as the Trump administration walks back enforcement.

Emma Achola-Kothari, PhD, explains that Medicare beneficiaries younger than 65 years without supplemental coverage face greater financial and access barriers to care, while dual-eligible individuals experience fewer of these challenges.

HHS announces it is taking steps to implement President Trump’s Executive Order on prescription drug pricing. Keep up with the latest moves made in health policy under President Donald Trump's second administration. This timeline will be updated as orders and policy progress.